Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01462305
Other study ID # CL-1033-SADGO-MS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 6, 2012
Est. completion date April 2, 2012

Study information

Verified date January 2019
Source Philips Respironics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD). It is hypothesized that the 467nm light will improve the symptoms of SAD better than the 580nm light.


Description:

Participants will be randomly assigned to receive either a 467nm light or a 580nm light. Participants will use the light every day for six weeks for 30 minutes. Multiple assessments and questionnaires will be given weekly to assess the efficacy of the treatment.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date April 2, 2012
Est. primary completion date April 2, 2012
Accepts healthy volunteers No
Gender All
Age group 21 Years to 64 Years
Eligibility Inclusion Criteria:

1. Males and females, ages 21-64

2. Able and willing to provide written informed consent

3. History of recurrent major depressive episodes with winter-type seasonal pattern by Diagnostic and Statistical Manual of the American Psychiatric Associated, 4th Ed. (DSM-IV) criteria (American Psychiatric Association, 1990), based on diagnostic interview utilizing the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al., 2007)

*Bipolar I excluded for this study

4. SIGH-ADS score of =20

5. Use of the light device as instructed by the study clinician for at least 6 out of 7 days for the first two weeks of therapy and at least 5 out of 7 days for the remaining four weeks of therapy.

Exclusion Criteria:

1. Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study

2. Subjects who are medically complicated, medically unstable and/or have other severe diseases, as determined by the investigator.

3. Abnormal TSH level, (outside range of 0.3 to 5.0 mlU/L), as determined by the TSH levels blood test

4. History of concurrent psychiatric illness that would preclude compliance with the protocol and/or ability to complete the study safely

5. History or current diagnosis of Bipolar I Disorder

6. Variable psychiatric symptoms such as rapid cycling or severe premenstrual syndrome that could interfere with accurate assessment of the treatment effect

7. History of a medical condition that affects mood or produces hallmark symptoms of a mood disorder (i.e. hypothyroidism)

8. History of current or recent (within previous 12 months) alcohol, narcotic or other drug abuse by DSM-IV criteria

9. Positive urine drug screen at the Physical Screening

10. Active suicidal or homicidal ideation or plan, as determined by the investigator

11. Global Assessment of Functioning (GAF) <51 (see Appendix B)

12. Use of light therapy treatment within the previous 6 months or any history of goLITE use

13. Pregnant or lactating (will confirm absence of pregnancy with a urine or serum pregnancy test in females of childbearing potential during the Physical Screening. Additional pregnancy tests may be performed as per individual site requirements). Females of child-bearing potential must agree to use some form of birth control throughout the course

14. Current use or use within 2 months of antidepressants or mood stabilizing medications, even if taken for a non-psychiatric indication

15. Currently working night shift or rotating shift or other habitual alteration of the sleep/wake cycle

16. Planned travel outside of the state in which the trial is being conducted

17. Current use or use within the previous 1 month of photosensitizing medications (amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin) or remedies (St. John's wort, melatonin)

18. History of eye trauma or disease, retinopathy, and/or cataract of a level that would significantly affect transmission or processing of light through either eye

19. Ishihara score of <10 on the Ishihara Test for Color Deficiency

20. Use of medications, such as tetracycline or oral isoretinoin (Accutane), that would affect the safety of light exposure treatment or that causes complaints of eyestrain or abnormal tearing with computer use of up to 30 minutes at a time

Study Design


Related Conditions & MeSH terms


Intervention

Device:
goLITE
goLITE at 30 minutes per day, within 30 minutes of waking in the morning
Control
light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks

Locations

Country Name City State
United States McLean Hospital Belmont Massachusetts
United States Brigham & Women's Hospital Boston Massachusetts
United States Community Research Management Associates Cincinnati Ohio
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Philips Respironics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary SIGH-ADS Score A Structured Interview Guide for the Hamilton Depression Scale with Atypical Depression Supplement was utilized at baseline and after 6 weeks of treatment.
The SIGH-ADS is designed for general use in depression research and clinical evaluation, regardless of seasonality.The SIGH-ADS rates the severity of depressive symptoms in terms of Hamilton's 17-item depression score and an 8-item atypical score. Combined this provides 25 items to provide the SIGH-ADS score. SIGH-ADS scores range from 0-79; higher values represent increased depression severity and worse outcome, the lower the score the less depressed the patient is. All participants that entered the study had to have a score of 20 or greater.
6 weeks
Secondary SIGH-ADS Score (Week 1 Thru 5) A Structured Interview Guide for the Hamilton Depression Scale with Atypical Depression Supplement was utilized weekly at in person visits or over the phone.
The SIGH-ADS is designed for general use in depression research and clinical evaluation, regardless of seasonality.The SIGH-ADS rates the severity of depressive symptoms in terms of Hamilton's 17-item depression score and an 8-item atypical score. Combined this provides 25 items to provide the SIGH-ADS score. SIGH-ADS scores range from 0-79; higher values represent increased depression severity and worse outcome and the lower the score the less depressed the patient is. All participants that entered the study had to have a score of 20 or greater.
weekly, from Week 1 through week 5
Secondary Q-LES-Q-SF The Q-LES-Q-SF (Quality of life enjoyment and satisfaction questionnaire short form) is a 16 question questionnaire that is enables investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning.
Responses to questions range from 1 to 5, 1 being very poor and 5 being very good. Scores range from 16 to 80, the higher score the higher the participants enjoyment and satisfaction.
6 weeks
See also
  Status Clinical Trial Phase
Completed NCT00502320 - Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder Phase 4
Completed NCT00046241 - Prevention of Seasonal Affective Disorder Phase 3
Completed NCT00006517 - Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD) N/A
Active, not recruiting NCT03691792 - Optimizing Long-Term Outcomes for Winter Depression With CBT-SAD and Light Therapy N/A
Completed NCT01462058 - The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff Phase 4
Recruiting NCT01030276 - Bright Light Therapy in Seasonal Affective Disorder (SAD) N/A
Completed NCT01149135 - Low Intensity 'Blue Light' Treatment of Seasonal Affective Disorder N/A
Completed NCT01292889 - Study of Genes in Relation to Seasonal Affective Disorder and Major Depressive Disorder N/A
Completed NCT01048294 - Blue Enriched Versus Standard Light Treatment for Seasonal Affective Disorder(SAD) N/A
Completed NCT02582398 - Influence of Light Exposure on Cerebral MAO-A in Seasonal Affective Disorder and Healthy Controls Measured by PET N/A
Completed NCT01293409 - Bright Light Therapy in Seasonal Affective Disorder (SAD) N/A
Active, not recruiting NCT00269633 - Research Study of Treatment for Winter Depression With Different Colors of Light Phase 2
Completed NCT00076245 - Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD) Phase 1
Completed NCT03313674 - Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD N/A
Completed NCT00016666 - Clinical Trial of Propranolol for Seasonal Affective Disorder Phase 2
Recruiting NCT00114322 - Light-Emitting Diode (LED) Light for Seasonal Affective Disorder (SAD) Treatment N/A
Completed NCT00001485 - Effects of Season on Melatonin Secretion in Healthy Men and Women and Patients With Seasonal Affective Disorder N/A
Completed NCT00139997 - Environmental Treatment for Seasonal Affective Disorder (SAD) N/A
Completed NCT04251000 - Infrared Photomodulation Therapy for Seasonal Affective Disorder N/A
Completed NCT00809523 - A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD) Phase 2/Phase 3